Penpulimab in Maintenance Therapy in Lymphoma

Inclusion Criteria:

1. Lymphoma patients who received transplantation or were intolerant to transplantation achieved remission after previous induction and consolidation therapy. Patients who were intolerant to transplantation here referred to lymphoma patients ≥60 years old or \< 60 years old and recommended for transplantation by the guidelines;
2. Age ≥18 years old;
3. ECOG PS\< 2 points;
4. Life expectancy is more than 3 months;
5. Patients were allowed to receive radiotherapy, but the last radiotherapy was given more than 7 days before the initial study drug administration;
6. Normal liver and kidney function, specific for direct bilirubin in serum, serum indirect bilirubin and/or cereal third transaminase, aspertate aminotransferase, serum creatinine 2 or less normal limit, creatinine clearance or ≥60 mL/min.
7. Normal bone marrow function, specific defined as absolute neutrophil count (ANC) acuity ≥1.0\*10\^9 / L, platelet ≥50 \*10\^9/L and ≥70 g/L or higher hemoglobin;
8. Women of childbearing age who used contraception or had a negative pregnancy test before enrollment, and who used contraception during the test period and within 8 weeks of the last drug administration; For men who were methodically contracepted or surgically sterilized during the trial period and 8 weeks after the last dose;
9. The subjects voluntarily joined the study and signed the informed consent with good compliance and follow-up.

Exclusion Criteria:

* 1\. Pregnant or lactating women;

  2\. Patients with a history of autoimmune diseases or syndromes requiring systemic use of steroid immunosuppressants, such as pituitaritis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism, hypothyroidism, etc.;

  3\. The patient had received systemic glucocorticoids (prednisone \&gt; 20mg/ day) therapy (excluding nasal spray, inhaled or other topical corticosteroids) or any other form of immunosuppressive therapy;

  4\. Uncontrolled heart disease, including unstable angina, acute myocardial infarction 6 months before randomization, congestive heart failure (NYHA) with a grade III or IV heart function; Or left ventricular ejection fraction \&lt; 50%;

  5\. Known allergy to test drug ingredients;

  6\. Patients receiving organ transplants;

  7\. Has been diagnosed with or is undergoing treatment for a malignancy other than lymphoma, except for:
  * had received treatment for the purpose of cure, and had no malignancies with known active disease for ≥5 years prior to enrollment;

    * Well-treated basal cell carcinoma of the skin with no signs of disease (except melanoma);

      * Well-treated carcinoma in situ of the cervix with no signs of disease.

        8\. Patients with grade 3 or above neurotoxic reactions in the two weeks prior to treatment;

        9\. Severely infected persons;

        10\. Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study or the evaluation of the study results;

        11\. Those who were considered unsuitable for inclusion by the researchers.